Lytix Biopharma: Mandatory notification of trade
Lytix Biopharma ASA (LYTIX) · publisert 2022-09-01 16:41 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| North Murray AS nærstående | Legal person closely associated with Gert W. Munthe Chairman in Lytix Biopharma | acquisition | 33 519 | 8,5656 NOK | – | NO0010405780 | MERK - Euronext Growth Oslo | rules · til gjennomgang |
Vedlegg
- Notification of Trade - 2022-09-01.pdf (tekst hentet ut)
Meldingstekst
Oslo, 1 September 2022, Lytix Biopharma AS, has today been notified that the following transaction has been completed by a primary insider in Lytix Biopharma AS: North Murray AS, a close associate of Gert W. Munthe, Chairman and primary insider in Lytix Biopharma AS, has bought 33,519 shares at an average price of NOK 8.5656 per share. After the transaction, North Murray AS holds 2,968,878 shares in Lytix Biopharma AS.
Please refer to the attached notification of trading for further details.
This information is subject to the disclosure requirements in the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact: Gjest Breistein, CFO, gjest.breistein@lytixbiopharma.no, +47 9526 0512